Oppenheimer resumed coverage on Harmony Biosciences with a new price target

6/2/25 8:52:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer resumed coverage of Harmony Biosciences with a rating of Outperform and set a new price target of $61.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HRMY

Date	Price Target	Rating	Analyst
6/2/2025	$61.00	Outperform	Oppenheimer
2/11/2025	$55.00	Buy	Deutsche Bank
12/17/2024	$75.00	Buy	H.C. Wainwright
10/10/2024		Outperform	Raymond James
9/10/2024	$56.00	Buy	UBS
6/21/2024	$48.00	Buy	Citigroup
1/2/2024	$30.00	Neutral → Underperform	BofA Securities
9/25/2023	$40.00 → $31.00	Neutral → Sell	Goldman